Raymond James Financial Inc. Raises Position in ADMA Biologics Inc $ADMA

Key Points

• Raymond James Financial Inc. increased its stake in ADMA Biologics by 18.7% in the first quarter, owning over 1.3 million shares valued at approximately $26.2 million.
• Multiple institutional investors are showing significant interest, with Envestnet Asset Management boosting its position by 68% during the fourth quarter.
• ADMA Biologics reported a solid quarterly EPS of $0.15, exceeding analysts' expectations, and achieved a 13.8% year-over-year revenue increase with $121.98 million in revenue.

Raymond James Financial Inc. grew its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 18.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,319,803 shares of the biotechnology company's stock after purchasing an additional 207,528 shares during the quarter. Raymond James Financial Inc. owned about 0.56% of ADMA Biologics worth $26,186,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. State of New Jersey Common Pension Fund D increased its holdings in ADMA Biologics by 22.5% during the 1st quarter. State of New Jersey Common Pension Fund D now owns 124,646 shares of the biotechnology company's stock worth $2,473,000 after purchasing an additional 22,893 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of ADMA Biologics by 12.7% in the 1st quarter. American Century Companies Inc. now owns 4,252,362 shares of the biotechnology company's stock worth $84,367,000 after buying an additional 478,800 shares during the last quarter. Fox Run Management L.L.C. lifted its stake in ADMA Biologics by 79.5% in the first quarter. Fox Run Management L.L.C. now owns 34,306 shares of the biotechnology company's stock valued at $681,000 after purchasing an additional 15,189 shares during the last quarter. Lord Abbett & CO. LLC lifted its stake in ADMA Biologics by 1.6% in the first quarter. Lord Abbett & CO. LLC now owns 2,241,623 shares of the biotechnology company's stock valued at $44,474,000 after purchasing an additional 34,346 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in ADMA Biologics by 152.7% in the first quarter. Russell Investments Group Ltd. now owns 1,632,675 shares of the biotechnology company's stock valued at $32,392,000 after purchasing an additional 986,666 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ADMA has been the topic of several research analyst reports. Raymond James Financial upped their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. According to data from MarketBeat, ADMA Biologics has an average rating of "Buy" and a consensus price target of $27.67.

Insiders Place Their Bets

In other news, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director owned 87,330 shares in the company, valued at $1,767,559.20. This trade represents a 69.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the transaction, the director owned 94,830 shares in the company, valued at $1,987,636.80. This represents a 17.42% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 455,621 shares of company stock valued at $9,461,633. Company insiders own 3.50% of the company's stock.

ADMA Biologics Stock Performance

ADMA traded down $0.12 during midday trading on Friday, hitting $17.26. 2,527,726 shares of the company traded hands, compared to its average volume of 3,388,413. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The firm has a market capitalization of $4.12 billion, a PE ratio of 20.07 and a beta of 0.38. The company's 50-day moving average is $17.76 and its 200 day moving average is $18.91.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. During the same quarter in the previous year, the firm posted $0.13 EPS. The firm's revenue was up 13.8% on a year-over-year basis. On average, research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.